Connection

David Cole to Drug Screening Assays, Antitumor

Back to Details
This is a "connection" page, showing publications David Cole has written about Drug Screening Assays, Antitumor.
David Cole
Connection Strength
0.026
Drug Screening Assays, Antitumor
  1. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.